Viking Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Viking Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 47.85K shares, a 44.19% increase year-over-year.
- Viking Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 48.94K shares, a 3.64% increase year-over-year.
- Viking Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 92.83K shares, a 32.33% decline year-over-year.
- Viking Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 41.25K shares, a 88.11% decline year-over-year.
- Viking Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 214.49K shares, a 87.43% decline from fiscal 2024.
- Viking Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 1.71M shares, a 22.36% increase from fiscal 2023.
- Viking Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 1.39M shares.
- Viking Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 0.00 shares, a 100.00% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 47.85K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | 230.87K shares derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | 48.94K shares 10-Q · filed 2026-04-30 | 216.21K shares derived: sum of 4 quarters · filed 2026-04-30 |
| 2025-12-31 | 92.83K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | 214.49K shares 10-K · filed 2026-02-11 |
| 2025-09-30 | 41.25K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-23 | 258.84K shares derived: sum of 4 quarters · filed 2026-02-11 |
| 2025-06-30 | 33.19K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-23 | 564.38K shares derived: sum of 4 quarters · filed 2026-02-11 |
| 2025-03-31 | 47.23K shares 10-Q · filed 2025-04-24 | 931.71K shares derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-12-31 | 137.18K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | 1.71M shares 10-K · filed 2026-02-11 |
| 2024-09-30 | 346.79K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-23 | 1.57M shares derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-06-30 | 400.51K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-24 | 1.22M shares derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-03-31 | 821.69K shares 10-Q · filed 2024-04-25 | 1.48M shares derived: sum of 4 quarters · filed 2026-02-11 |
| 2023-12-31 | 125.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | 1.39M shares 10-K · filed 2026-02-11 |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-25 | 1.39M shares derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | 655.87K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-26 | 1.39M shares derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | 738.42K shares 10-Q · filed 2023-04-26 | 738.42K shares derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | 0.00 shares 10-K · filed 2025-02-26 |
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-26 | 0.00 shares derived: sum of 4 quarters · filed 2024-02-07 |
| 2022-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-27 | 3.25K shares derived: sum of 4 quarters · filed 2024-02-07 |
| 2022-03-31 | 0.00 shares 10-Q · filed 2022-04-27 | 63.00K shares derived: sum of 4 quarters · filed 2024-02-07 |
| 2021-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-07 | 107.70K shares 10-K · filed 2024-02-07 |
| 2021-09-30 | 3.25K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | 107.70K shares derived: sum of 4 quarters · filed 2022-02-09 |
| 2021-06-30 | 59.75K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-28 | 149.45K shares derived: sum of 4 quarters · filed 2022-02-09 |
| 2021-03-31 | 44.70K shares 10-Q · filed 2021-04-28 | 120.83K shares derived: sum of 4 quarters · filed 2022-02-09 |
| 2020-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | 86.13K shares 10-K · filed 2022-02-09 |
| 2020-09-30 | 45.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-28 | 88.63K shares derived: sum of 4 quarters · filed 2021-02-17 |
| 2020-06-30 | 31.13K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-29 | 86.53K shares derived: sum of 4 quarters · filed 2021-02-17 |
| 2020-03-31 | 10.00K shares 10-Q · filed 2020-04-30 | 66.90K shares derived: sum of 4 quarters · filed 2021-02-17 |
| 2019-12-31 | 2.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-17 | 82.34K shares 10-K · filed 2021-02-17 |
| 2019-09-30 | 42.90K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | 79.84K shares derived: sum of 4 quarters · filed 2020-02-26 |
| 2019-06-30 | 11.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | 58.04K shares derived: sum of 4 quarters · filed 2020-02-26 |
| 2019-03-31 | 25.44K shares 10-Q · filed 2019-05-02 | 152.61K shares derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | 171.57K shares 10-K · filed 2020-02-26 |
| 2018-09-30 | 21.10K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | 193.60K shares derived: sum of 4 quarters · filed 2019-03-13 |
| 2018-06-30 | 106.07K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | 172.49K shares derived: sum of 4 quarters · filed 2019-03-13 |
| 2018-03-31 | 44.39K shares 10-Q · filed 2018-05-09 | 66.42K shares derived: sum of 4 quarters · filed 2019-03-13 |
| 2017-12-31 | 22.03K shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13 | 22.03K shares 10-K · filed 2019-03-13 |
| 2017-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | |
| 2017-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | |
| 2017-03-31 | 0.00 shares 10-Q · filed 2018-05-09 | |
| 2016-12-31 | 0.00 shares 10-K · filed 2018-03-07 | |
| 2015-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |